Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience
- 24 November 2019
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 42 (4), 599-607
- https://doi.org/10.1002/hed.26026
Abstract
Background Salivary gland cancers (SGCs) are rare. The approach to metastatic patients is histology‐dependent. There is little evidence on whether next‐generation sequencing (NGS) findings translate to tumor control in SGCs. Methods We analyzed all patients with histologically confirmed SGC who underwent NGS. Results Twenty‐seven patients were identified, 14 (51.8%) had targetable findings in NGS: 5 ERBB2 amplifications, 3 PIK3CA mutations, 2 RUNX1 mutations, 1 TRIM33‐RET fusion, 1 FGFR3‐TACC3 fusion, 1 microsatellite instability‐high, and 2 high mutational burden. Ten patients were treated accordingly. Median progression‐free survival for targeted treatment was 8.4 months. Of five patients who achieved durable responses of 8.4 to 31.3 months, two are ongoing. The overall median survival was not reached for patients receiving targeted treatment and was 40.4 months for patients treated conventionally (P = .18). Conclusions In the absence of a well‐established therapeutic approach, NGS may detect clinically significant genetic alterations and benefit patients with advanced SGC.Keywords
This publication has 32 references indexed in Scilit:
- p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other MalignanciesSeminars in Oncology, 2012
- Androgen Receptor–Positive Salivary Duct Carcinoma: A Disease Entity With Promising New Treatment OptionsJournal of Clinical Oncology, 2011
- Oncogenic Mutations of PIK3CA in Human CancersPublished by Springer Science and Business Media LLC ,2010
- Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)Oral Oncology, 2009
- Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary GlandsJournal of Clinical Oncology, 2007
- Systemic Therapy in the Palliative Management of Advanced Salivary Gland CancersJournal of Clinical Oncology, 2006
- Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology GroupHead & Neck, 2006
- World Health Organization classification of tumours: Pathology & genetics of tumours of the urinary system and male genital organsUrology, 2005
- Salivary gland tumoursOral Diseases, 2002
- Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinomaAnnals of Oncology, 1996